3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
Nivolumab
74
Sunitinib
73
pembrolizumab
49
Everolimus
39
Sorafenib
36
Bevacizumab
36
Axitinib
36
cabozantinib
35
Radiosurgery
33
Ipilimumab
33
pazopanib
32
Magnetic Resonance Spectroscopy
27
Interleukin-2
27
aldesleukin
23
Specimen Handling
22
Cyclophosphamide
21
lenvatinib
20
fludarabine phosphate
17
Radiotherapy
16
Interferon-alpha
15
Peripheral Blood Stem Cell Transplantation
14
Gemcitabine
14
Biopsy
14
temsirolimus
13
Nephrectomy
13
durvalumab
11
Immunohistochemistry
11
CTLA-4 Antigen
11
Blood Specimen Collection
11
Capecitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Renal Cell
×
dostarlimab
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled